RNF8: ¿BLANCO TERAPÉUTICO POTENCIAL PARA TRATAR EL CÁNCER DE MAMA?
DOI:
https://doi.org/10.18633/biotecnia.v20i1.529Palabras clave:
53bp1, brca1, rnf8, cáncer de mamaResumen
El cáncer de mama hereditario se ha asociado con alteraciones en el gen BRCA1, imposibilitando a la célula tumoral reparar las lesiones de doble cadena del ADN por recombinación homóloga. En la célula normal la RH es necesaria para el mantenimiento de la integridad del ADN. Sin embargo, en las células con BRCA1 disfuncional, el ADN es reparado por el sistema de unión de extremos no homólogos propenso a errores en la0reparación del ADN. Esta condición involucra a 53BP1, cuya función es esencial para el sistema UENH, favoreciendo la inestabilidad genómica y la tumorigénesis mamaria. RNF8 es una E3 ubiquitina ligasa que promueve el enlace de BRCA1 y 53BP1 ubicándolas en los sitios de ADN dañado. Se presentan una serie de alternativas con el objetivo de reconocer y promover la eliminación de RNF8. Estas aproximaciones presentan a RNF8 como blanco en estrategias farmacológicas para eliminar la inestabilidad genómica dependiente de 53BP1 y la resistencia farmacológica promovida por la inactivación de 53BP1 en células mamarias carentes de BRCA1.
Descargas
Citas
Anduro-Corona, I. 2012. Efecto del gen RNF8 en el desarrollo
del cáncer de mama. [Tesis doctoral inédita]. Universidad de
Sonora, Hermosillo.
Bee, L., Fabris, S., Cherubini, R., Mognato, M. y Celotti, L. 2013. The Efficiency of Homologous Recombination and Non Homologous End Joining Systems in Repairing Double Strand Breaks during Cell Cycle Progression. PLoS ONE. 8: e69061. doi: 10.1371/journal.pone.0069061.
Bernstein, C. y Bernstein, H. 2015. Epigenetic reduction of DNA repair in progression to gastrointestinal cancer. World Journal of Gastrointestinal Oncology. 7: 30–46.
Bunting, S. F., Callen, E., Wong, N., Chen, H. T., Polato, F., Gunn, A., et al. 2010. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell. 141: 243–254. doi: 10.1016/j.cell.2010.03.012.
Botuyan, M. V., Lee, J., Ward, I. M., Kim, J. E., Thompson, J. R., Chen, J., et al. 2006. Structural Basis for the Methylation State-Specific Recognition of Histone H4-K20 by 53BP1 and Crb2 in DNA Repair. Cell. 127: 1361–1373. doi: 10.1016/j. cell.2006.10.043.
Bouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J.,
van der Gulden, H., et al. 2010. 53BP1 loss rescues BRCA1
deficiency and is associated with triple-negative and BRCAmutated breast cancers. Nature Structural & Molecular Biology. 17: 688–695. doi: 10.1038/nsmb.1831.
Chatterjee, G., Jimenez-Sainz, J., Presti, T., Nguyen, T. y Jensen, R. B. 2016. Distinct binding of BRCA2 BRC repeats to RAD51 generates differential DNA damage sensitivity. Nucleic Acids Research. 44: 5256–5270. doi: 10.1093/nar/gkw242.
Chen, J., Morrical, M. D., Donigan, K. A., Weidhaas, J. B., Sweasy, J. B., Averril, A. M., et al., 2015. Tumor-associated mutations in a conserved structural motif alter physical and biochemical properties of human RAD51 recombinase. Nucleic Acids Research. 43: 1098–1111. doi: 10.1093/nar/gku1337.
Chin, C. F. y Yeong, F. M. 2010. Safeguarding entry into mitosis:
the antephase checkpoint. Molecular and Cellular Biology.
: 22–32. Comen, E., Davids, M., Kirchhoff, T., Hudis, C., Offit, K. y Robson, M. 2011. Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi Women.
Breast Cancer Research and Treatment. 129: 185–190.
Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., et al. 2015. Breast cancer
intrinsic subtype classification, clinical use and future trends. American Journal of Cancer Research. 5: 2929–2943.
Doil, C., Mailand, N., Bekker-Jensen, S., Menard, P., Larsen, D. H., Pepperkok, R., et al. 2009. RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins. Cell. 136: 435–446.
Draga, M., Madgett, E. B., Vandenberg, C. J., du Plessis, D., Kaufmann, A., Werler, P., et al. 2015. BRCA1 Is Required for Maintenance of Phospho-Chk1 and G2/M Arrest during
DNA Cross-Link Repair in DT40 Cells. Molecular and Cellular
Biology. 35: 3829–3840.
Eliezer, Y., Argaman, L., Kornowsky M., Roniger, M. y Goldberg
M. 2014. Interplay between the DNA Damage Proteins MDC1 and ATM in the Regulation of the Spindle Assembly Checkpoint. The Journal of Biological Chemistry. 289: 8182–8193.
Fattah, F., Lee, E. H., Weisensel, N., Wang, Y., Lichter, N. y Hendrickson, E. A. 2010. Ku Regulates the Non-Homologous End Joining Pathway Choice of DNA Double-Strand Break Repair in Human Somatic Cells. PLoS Genetics. 6: e1000855. doi: 10.1371/journal.pgen.1000855.
Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., et al. GLOBOCAN. [Consultado el 17 de julio 2017] 2014.v1.0. Cancer Incidence and Mortality Worldwide: IARC
CancerBase No. 11. Disponible en: http://globocan.iarc.fr.
Fradet-Turcotte, A., Canny, M. D., Escribano-Díaz, C., Orthwein,
A., Leung, C. C. Y., Huang, H., et al. 2013. 53BP1 is a reader of the DNA-damage-induced H2A lys 15 ubiquitin mark.
Nature. 499: 50–54.
Gavande, N. S., VanderVere-Carozza, P. S., Hinshaw, H. D., Jalal, S. I., Sears, C. R., Pawelczak, K. S., et al. 2016. DNA repair targeted therapy: the past or future of cancer treatment?. Pharmacology & Therapeutics. 160: 65–83. doi: 10.1016/j.pharmthera.2016.02.003.
Giunta, S., Belotserkovskaya, R. y Jackson, S. P. 2010. DNA damage signaling in response to double-strand breaks during mitosis. The Journal of Cell Biology. 190: 197–207.
Giunta, S., y Jackson, S. P. 2011. Give me a break, but not in
mitosis: the mitotic DNA damage response marks DNA double strand breaks with early signaling events. Cell Cycle.
: 1215–1221.
Guo, X., Wang, X., Wang, Z., Benerjee, S., Yan, J., Huang, L., et al.
Site-specific Proteasome Phosphorylation Controls Cell Proliferation and Tumorigenesis. Nature Cell Biology. 18: 202–212. doi: 10.1038/ncb3289.
Hanahan, D. y Weinberg, R. A. 2011. Hallmarks of cancer: the next generation. Cell. 144: 646–674.
Hodge, C. D., Spyracopoulos, L. y Grover, J. N. M. 2016. Ubc13:
the Lys63 ubiquitin chain building machine. Oncotarget. 7: 64471–64504.
Huen, M. S., Grant, R., Manke, I., Minn, K., Yu, X., Yaffe, M. B., et al. 2007. RNF8 transduces the DNA-damage signal via histone
ubiquitylation and checkpoint protein assembly. Cell. 131: 901–14.
INEGI. 2015. Estadísticas de mortalidad. Cubos dinámicos. Iwabuchi, K., Hashimoto, M., Matsui, T., Kurihara, T., Shimizu, H.,
Adachi, N. et al. 2006. 53BP1 contributes to survival of cells irradiated with X-ray during G1 without Ku70 or Artemis. Genes to Cells. 11: 935–948.
Jaspers, J. E., Kersbergen, A., Boon, U., Sol, W., van Deemter, L., Zander, S. A., et al 2013. Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors. Cancer Discovery. 3: 68–81.
Kim, J. H., Grosbart, M., Anand, R., Wyman, C., Cejka, P. y Petrini, H. J. H. 2017. The Mre11-Nbs1 interface is essential for viability and tumor suppression. Cell Reports. 18: 496–507. doi: 10.1016/j.celrep.2016.12.035.
Kolas, N. K., Chapman, J. R., Nakada, S., Ylanko, J., Chahwan, R., Sweeney, F. D., et al. 2007. Orchestration of the DNAdamage response by the RNF8 ubiquitin ligase. Science. 318: 1637–1640.
Kuang, J., Li, L., Guo, L., Su, Y., Wang, Y., Xu, Y., et al. 2016. RNF8
promotes epithelial-mesenchymal transition of breast cancer cells. Journal of Experimental & Clinical Cancer Research. 35: 88. doi: 10.1186/s13046-016-0363-6.
Lara-Medina, F., Perez-Sanchez, V., Saavedra-Perez, D., Blake-
Cerda, M., Arce, C., Motola-Kuba, D., et al. 2011. Triplenegative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 117: 3658–3669.
Lee, H. J., Li, C. F., Ruan, D., Power, S., Thompson, P. A., Frohman, M. A., et al. 2016a. The DNA Damage Transducer RNF8 Facilitates Cancer Chemoresistance and Progression through Twist Activation. Molecular Cell. 63: 1021–1033.
Lee, H. J., Ruan, D., He, J. y Chan, C. H. 2016b. Two-faced activity
of RNF8: What “twists” it from a genome guardian to a cancer
facilitator?. Molecular & Cellular Oncology. 3: e1242454. doi: 10.1080/23723556.2016.1242454.
Li, L., Zhong, Y., Zhang, H., Yu, H., Huang, Y., Li, Z., et al. 2017.
Association between oral contraceptive use as a risk factor and triple-negative breast cancer: A systematic review and meta-analysis. Molecular and Clinical Oncology. 7: 76–80. doi: 10.3892/mco.2017.1259.
Lilley, C. E., Chaurushiya, M. S., Boutell, C., Landry, S., Suh, J., Panier, S., et al. 2010. A viral E3 ligase targets RNF8 and RNF168 to control histone ubiquitination and DNA damage responses. The EMBO Journal. 29: 943–955.
Mao, Z., Jiang, Y., Liu, X., Seluanov, A., Gorbunova, V. 2009. DNA repair by homologous recombination, but not by nonhomologous
end joining, is elevated in breast cancer cells. Neoplasia. 11: 683–691.
Nelson-Moseke, A. C., Jeter, J. M., Cui, H., Roe, D. J. Chambers,
S. K. y Laukaitis, C. M. 2013. An Unusual BRCA Mutation Distribution in a High Risk Cancer Genetics Clinic. Familial
Cancer. 12: 83–87. doi: 10.1007/s10689-012-9581-z.
Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D.,
Zou, X., et al. 2016. Landscape of somatic mutations in 560
breast cancer whole-genome sequences. Nature. 534: 47–54.
doi: 10.1038/nature17676.
Plans, V., Guerra-Rebollo, M. y Thomson, T. M. 2008. Regulation
of mitotic exit by the RNF8 ubiquitin ligase. Oncogene. 27: 1355–1365.
Pern, F., Bogdanova, N., Schurmann, P., Lin, M., Ay, A., Langer, F., Hillemanns, P. et al. 2012. Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of german patients with Triple-Negative breast cancer. PLOS ONE. 7: e47993. doi: 10.1371/journal.pone.0047993.
Rai, R., Li, J. M., Zheng, H., Lok, G. T., Deng, Y., Huen, M. S., et al. 2011. The E3 ubiquitin ligase Rnf8 stabilizes Tpp1 to promote
telomere end protection. Nature Structural & Molecular Biology. 18: 1400–1407.
Reuter, M., Zelensky, A., Smal, I., Meijering, E., van Cappellen, W. A., de Gruiter, M. H., et al. 2014. BRCA2 diffuses as oligomeric clusters with RAD51 and changes mobility after DNA damage in live cells. The Journal of Cell Biology. 207: 599–613.
Scheper, J., Guerra-Rebollo, M., Sanclimens, G., Moure, A., Masip,
I., González-Ruiz, D., et al. 2010. Protein-Protein Interaction Antagonists as Novel Inhibitors of Non-Canonical Polyubiquitylation. PLOS ONE. 5: e11403. doi: 10.1371/
journal.pone.0011403.
Soruvtseva, Y. V., Jairan, V., Salem, A. F., Sundaram, R. K., Bindra, R. S. y Herzon, S. V. 2016. Characterization of Cardiac Glycoside
Natural Products as Potent Inhibitors of DNA Double-Strand Break Repair by a Whole-Cell Double Immunofluorescence Assay. Journal of the American Chemical Society. 23: 3844–3855. doi: 10.1021/jacs.6b00162.
Tischkowitz, M., Sabbaghian, N., Hamel, N., Pouchet, C., Foulkes, W. D., Mes-Masson, A. M., et al. 2013. Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in welldefined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent. BMC Medical Genetics. 14. doi: 10.1186/1471-2350-14-5.
Toffoli, S., Bar, I., Abdel-Sater, F., Delrée, P., Hilbert, P., Cavallin, F., et al. 2014. Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
Breast Cancer Research 2014, 16: 466.
Tuttle, R. L., Bothos, J., Summers, M. K., Luca, F. C., y Halazonetis, T. D. 2007. Defective in mitotic arrest 1/RING finger 8 is a
checkpoint protein that antagonizes the human mitotic exit network. Molecular Cancer Research. 5: 1304–1311.
Villareal-Garza, C., Weitzel, J. N., Llacuachaqui, M., Sifuentes,
E., Magallanes-Hoyos, M. C., Gallardo, L., et al. 2015. The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer. Breast Cancer Research and Treatment. 150: 389–394. doi: 10.1007/ s10549-015-3312-8.
Wang, S., Luo, H., Wang, C., Sun, H., Sun, G., Sun, N., et al. 2017. RNF8 identified as a co-activator of estrogen receptor α promotes cell growth in breast cancer. Biochimica et Biophysica Acta. 1863: 1615–1628.
Wang, Z., Yin, H., Zhang, Y., Feng, Y., Yan, Z., Jiang, X., et al. 2014. miR-214-mediated downregulation of RNF8 induces chromosomal instability in ovarian cancer cells. Cell Cycle.
: 3519–3528. doi: 10.4161/15384101.2014.958413.
Weber, E., Rothenaigner, I., Brandner, S., Hadian, K. y Schorpp,
K. 2017. A High-Throughput Screening Strategy for Development of RNF8-Ubc13 Protein–Protein Interaction Inhibitors. SLAS Discovery. 22: 316–323. doi: 10.1177/1087057116681408.
Xia, J., Yang, W., Fa, M., Li, X., Wang, W., Jiang, Y., et al. 2017. RNF8 mediates histone H3 ubiquitylation and promotes glycolysis
and tumorigenesis. J. Exp. Med. doi: 10.1084/jem.20170015.
Yan, Y., Spieker, R. S., Kim, M., Stoeger, S. M. y Cowan, K. H. 2005.
BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation. Oncogene. 24: 3285–3296.
Yoshioka, T., Kimura, M., Saio, M., Era, S. y Okano, Y. 2011. Plk1 is negatively regulated by RNF8. Biochemical and Biophysical Research Communications. 410: 57–61.
Zhang, F., Ma, J., Wu, J., Ye, L., Cai, H., Xia, B., et al. 2009. PALB2
links BRCA1 and BRCA2 in the DNA-damage response. Current Biology. 19: 524–529.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
La revista Biotecnia se encuentra bajo la licencia Atribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0)
_(2).jpg)
